News & Updates
Filter by Specialty:

Thrice/week on par with twice/week ultrasound therapy for erectile dysfunction
Low-intensity pulsed ultrasound therapy three times per week has comparable therapeutic effects and safety as that of a twice-a-week session for mild-to-moderate erectile dysfunction (ED) in young and healthy men, reports a study.
Thrice/week on par with twice/week ultrasound therapy for erectile dysfunction
22 Oct 2022
Kidney transplant recipients see lower IgG production after COVID-19 jab
Vaccination against COVID-19 seems to be less effective among kidney transplant recipients, according to a recent study. Cessation or reduction of immunosuppressive treatments may help increase the production of immunoglobulin (Ig)G in these patients.
Kidney transplant recipients see lower IgG production after COVID-19 jab
14 Oct 2022
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022
ADT suppresses levels of several androgen precursor steroids
In prostate cancer patients, the initiation of androgen deprivation therapy (ADT) lowers the concentrations of 13 circulating steroids, according to a new study.
ADT suppresses levels of several androgen precursor steroids
04 Oct 2022
Secondary kidney stones: to remove or not?
Pre-emptive removal of secondary* kidney stones during surgery to remove primary** stones led to fewer relapses and a similar number of emergency-department (ED) visits related to the surgery compared with leaving the secondary stones in place, a study suggests.
Secondary kidney stones: to remove or not?
30 Sep 2022
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
Some men who undergo artificial urinary sphincter (AUS) and inflatable penile prosthesis (IPP) surgery encounter a venous thromboembolism (VTE) event within 90 days of their operation, reports a study.
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
27 Sep 2022
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
Treatment with radiotherapy appears to result in more all-cause or prostate cancer-specific mortality (PCSM) compared with radical prostatectomy (RP), suggests a study.